Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance

Journal of Hepatology

Volumn 33, Issue 3, 2000, Pages 469-475

  Gutfreund, Klaus S ^a   Williams, Mark ^a,b   George, Rajan ^a,b   Bain, Vincent G ^a   Ma, Mang M ^a   Yoshida, Eric M ^c   Villeneuve, Jean Pierre ^b   Fischer, Karl P ^a,b   Tyrrell, David L J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiviral agents; Drug resistance; Hepatitis B virus (HBV); Lamivudine; Mutations; Nucleoside analogs; Polymerase

Indexed keywords

DNA POLYMERASE; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRAL GENETICS; VIREMIA; VIRUS STRAIN;

EID: 0033845357     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80284-6     Document Type: Article

References (42)

1. Natural history and control of perinatally aquired hepatitis B virus infection
2. Hepatitis B: Global importance and need for control
3. Global status of hepatitis B immunization
4. Effects of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: A metaanalysis
5. Therapy of viral hepatitis
6. Drug therapy: The treatment of chronic viral hepatitis
7. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
8. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma
9. Treatment of chimpanzees and ducks with lamivudine, 2'3'-dideoxy 3'-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera
10. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues
11. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication
12. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine
13. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)- beta-L-2',3'-dideoxy-3'-thiacytidine
14. Comparative biology and pathogenesis of AIDS and hepatitis B viruses: Related but different
15. Hepatitis B virus replication
16. Phase II trial of lamivudine for chronic hepatitis B
17. A preliminary trial of lamivudine for chronic hepatitis B infection
18. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
19. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
20. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
21. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
22. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
23. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
24. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
25. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
26. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
27. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
28. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] in vitro
29. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
30. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
31. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation
32. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
33. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
34. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
35. Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: Long-term follow-up
36. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays
37. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
38. Clinical experience with famciclovir against hepatitis B virus
39. Gucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells
40. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro
41. Mutational pattern of hepatitis B virus on the sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
42. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy